Credit Suisse

NEW YORK (GenomeWeb News) – Credit Suisse today upgraded Myriad Genetics' stock and raised the price target on its shares, while it downgraded Genomic Health and lowered the price target on that firm's shares.

NEW YORK (GenomeWeb News) – Investment bank Credit Suisse today upgraded shares of Sequenom to Neutral, noting the non-invasive prenatal fetal aneuploidy testing firm's announcement of its national contract with

NEW YORK (GenomeWeb News) – Investment bank Credit Suisse today initiated coverage of Agilent Technologies with an Outperform rating and a $48 price target.

NEW YORK (GenomeWeb News) – Credit Suisse on Monday initiated coverage of Genomic Health with an Outperform rating, Myriad Genetics with a Neutral rating, and Sequenom with an Underperform rating.

NEW YORK (GenomeWeb News) – Investment bank Credit Suisse today upgraded Illumina's stock, citing the firm's improved financial performance over the past two quarters and the potential of its tools for the clinical market in the longer term.

The firm launched three microRNA-based tests during the fourth quarter, and posted a profit due to a capital gain on the sale of Auction Rate Securities to Credit Suisse. However, Rosetta only has enough cash to fund operations through mid-2010 and said that it may seek to raise additional funds.

Agilent's shares soared along with the broader market on Monday, while Celera's stock dropped. Even though an analyst upgraded the stock, he also lowered his revenues and EPS estimates for the firm.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.